8-K: EyePoint Doses First Patients in Phase 3 DME Trials

EyePoint, Inc. announced the dosing of the first patients in its global Phase 3 clinical trials, COMO and CAPRI, for DURAVYU (vorolanib intravitreal insert) in diabetic macular edema (DME).

Summary

• EyePoint, Inc. has dosed the first patients in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).
• DURAVYU is an investigational sustained delivery therapy that delivers vorolanib, a selective tyrosine kinase inhibitor (TKI) with a multi-mechanism of action, inhibiting VEGF-mediated vascular permeability, PDGF, and IL-6 mediated inflammation.
• The DME Phase 3 program consists of two global, randomized, double-masked, aflibercept controlled non-inferiority trials (COMO and CAPRI), each enrolling approximately 240 patients.
• Patients in the DURAVYU 2.7mg arm will be re-dosed every six months via a single standard intravitreal injection.
• The primary endpoint for these trials is a non-inferior change from baseline in best corrected visual acuity (BCVA) to weeks 52 and 56, blended versus aflibercept control.
• Topline data for DURAVYU in DME is anticipated in the second half of 2027.
• The company's Phase 3 trials for wet age-related macular degeneration (wet AMD), LUGANO and LUCIA, are fully enrolled, with topline data expected beginning in mid-2026.
• EyePoint has approximately $300 million in cash and investments, which is expected to support its operating runway into Q4 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, marking a critical progression in EyePoint's clinical pipeline for a significant market, supported by a unique therapeutic approach and solid financial runway.

Positives

• Achieved a significant milestone by dosing the first patients in both global Phase 3 DME trials (COMO and CAPRI) for DURAVYU.
• DURAVYU is the only TKI in Phase 3 clinical trials for DME, solidifying EyePoint's leadership in sustained-release ocular drug delivery.
• DURAVYU offers a novel, multi-mechanism of action (inhibiting VEGF, PDGF, and IL-6 mediated inflammation), addressing unmet needs beyond existing anti-VEGF therapies.
• Designed to provide consistent dosing for at least six months, potentially reducing treatment burden for patients.
• The DME pivotal program was informed by positive Phase 2 VERONA results and has alignment with both the FDA and EMA.
• A strong safety profile has been observed in over 190 patients across four completed clinical trials, with no DURAVYU-related ocular or systemic severe adverse events (SAEs).
• Cash and investments of approximately $300 million (as of December 31, 2025) support operations into Q4 2027.
• Commercial manufacturing scale-up is underway in a state-of-the-art US facility to support potential NDA approval and commercial launch.

Risks

• The timing, progress, and results of the company's clinical development activities, including DURAVYU, are uncertain.
• Uncertainties and delays relate to communications with the U.S. Food and Drug Administration (FDA) and the ability to obtain regulatory approval for DURAVYU.
• Unanticipated costs and expenses may arise during development and commercialization.
• The company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated.
• Results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change.
• Unexpected safety or efficacy data could be observed during clinical trials.
• Uncertainties exist regarding the regulatory authorization or approval process and available development and regulatory pathways for product candidates.
• Changes in the regulatory environment, including disruptions at the FDA, could impact the business.
• Changes in U.S. and international trade policies may affect operations.
• Changes in expected or existing competition could impact market share.
• The success of current and future license agreements is not guaranteed.
• Dependence on contract research organizations and other outside vendors and service providers poses risks.
• Product liability claims could arise.
• The impact of general business and economic conditions may affect financial performance.
• Protecting intellectual property and avoiding infringement are ongoing challenges.
• Retention of key personnel is crucial for continued success.
• Delays, interruptions, or failures in the manufacture and supply of product candidates could occur.
• The availability of and the need for additional financing are potential concerns.
• The ability to obtain additional funding to support clinical development programs is uncertain.
• Uncertainties exist regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties exist regarding the FDA warning letter pertaining to the Watertown, MA manufacturing facility.

Future Outlook

EyePoint anticipates topline data for its wet AMD Phase 3 trials (LUGANO and LUCIA) beginning in mid-2026 and for its DME Phase 3 trials (COMO and CAPRI) in the second half of 2027. The company believes DURAVYU is well-positioned to be the first-to-market among investigational sustained-release treatments for wet AMD and DME, offering a novel multi-mechanism of action and 6-month durability. EyePoint expects its current cash and investments to fund operations into Q4 2027.

Management Comments

• "Dosing of the first patients in our two pivotal DME trials represents a significant milestone for EyePoint and DURAVYU the only TKI in Phase 3 clinical trials for DME and solidifies our leadership in sustained-release ocular drug delivery." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer of EyePoint.
• "There is a clear need for more durable and differentiated treatment options for patients with DME... DURAVYU's multi-MOA uniquely targets inflammation through inhibition of IL-6/JAK1 signaling while also reducing vascular leakage through blocking of all VEGF receptors... In addition, DURAVYU is designed to provide consistent dosing for at least six months, potentially helping to protect vision between visits." David Eichenbaum, M.D., Principal Investigator in the CAPRI clinical trial.

Industry Context

StockSavvy.ai notes that the retinal disease market, particularly for wet AMD and DME, represents a multi-billion-dollar opportunity with a clear need for more durable and differentiated treatment options. Current anti-VEGF therapies often require frequent injections, leading to significant treatment burden and suboptimal long-term vision outcomes for many patients. DURAVYU's sustained-delivery, multi-mechanism of action (targeting VEGF, PDGF, and IL-6) positions it to potentially address these unmet needs by offering longer duration and a broader therapeutic approach compared to existing ligand-blocking anti-VEGFs.

Comparison to Industry Standards

• DURAVYU aims to provide 6-month durability, which is significantly longer than current standard-of-care anti-VEGF biologics like Lucentis (~30 days), Eylea (~44 days), and Vabysmo (~57 days), which have year 3 sales of $1.8B, $3.3B, and $4.3B respectively, indicating market reward for improved durability.
• DURAVYU's multi-MOA (inhibiting VEGF receptors, PDGF, and IL-6 signaling) differentiates it from current ligand-blocking anti-VEGF therapies and other investigational sustained delivery programs. For example, OTX-TKI, ABBV-RGX-314, ADVM-022, 4D-150, Tarcocimab tedromer, KSI-501, and Port delivery system (ranibizumab) primarily focus on VEGF inhibition, with some also targeting PDGF, but DURAVYU uniquely combines VEGF, PDGF, and IL-6 inhibition with 6-month durability.
• The Phase 3 trial design for DME (COMO and CAPRI) and wet AMD (LUGANO and LUCIA) follows an established non-inferiority regulatory pathway against on-label aflibercept, a widely used anti-VEGF therapy.
• VERONA Phase 2 DME results showed comparable visual acuity with a single DURAVYU dose (plus aflibercept on Day 1) to twelve monthly injections of Vamikibart (anti-IL6) + ranibizumab in the BARDENAS Phase 2 trial, highlighting potential for reduced treatment burden.

Legal Proceedings

• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties regarding the FDA warning letter pertaining to the Watertown, MA manufacturing facility.

Stakeholder Impact

• Shareholders: Positive impact due to the progression of key clinical assets, potential for future market leadership, and clear development timelines.
• Patients (with DME/wet AMD): Potential for a new, more durable, and effective treatment option that could reduce treatment burden and improve vision outcomes.
• Physicians: Offers a novel therapeutic approach and a sustained-release option that could simplify treatment regimens.
• Employees: Continued progress in clinical development supports job security and potential for company growth.

Next Steps

• Full enrollment of DURAVYU Phase 3 DME trials (COMO and CAPRI) anticipated in 2H 2026.
• Topline 56-week data for LUGANO (wet AMD) expected mid-2026.
• Topline data for LUCIA (wet AMD) anticipated shortly after LUGANO.
• Topline data for DURAVYU in DME anticipated in 2H 2027.
• DURAVYU registration batches are underway to support anticipated NDA filing.
• Tox and PK data for EYP-2301 (razuprotafib intravitreal insert) are expected in 2026.

Key Dates

Recommendation

The initiation of Phase 3 trials for DURAVYU in DME, coupled with the advanced status of wet AMD trials, positions EyePoint for significant future growth in multi-billion dollar markets. DURAVYU's unique multi-MOA and 6-month sustained delivery address critical unmet needs, offering a potential best-in-class profile. The company's solid cash runway into Q4 2027 provides stability for these development efforts. While clinical trials carry inherent risks, the progress and differentiation of DURAVYU warrant a strong buy recommendation for long-term investors.

Keywords

Diabetic Macular Edema, DME, DURAVYU, Vorolanib, Tyrosine Kinase Inhibitor, TKI, Phase 3 Clinical Trials, Retinal Disease, Sustained Delivery, Anti-VEGF, EyePoint Inc, Biopharmaceutical, Ophthalmology, Wet AMD, Age-related Macular Degeneration, Durasert E